Listen on the go
CORRECT!
Next question
touchIMMUNOLOGY touchIMMUNOLOGY

Start Learning

Touch Loading image
European Commission approval of upadacitinib 15 mg for the treatment of giant cell arteritis in adult patients
JOURNALS
Start Learning
European Commission approval of upadacitinib 15 mg for the treatment of giant cell arteritis in adult patients
CONFERENCE HUB
Start Learning
Bimekizumab on structural damage in r-axial SpA & remote monitoring vs face-to-face
CONFERENCE HUB
Start Learning
Efficacy and safety of izokibep: An investigational IL-17A inhibitor
JOURNALS
Start Learning
Optimizing Tumour Necrosis Factor Inhibitor Therapy in Rheumatoid Arthritis: Embracing Personalized Medicine
Medics for Rare Disease
JOURNALS
Start Learning
Medics For Rare Disease – New Year, New Strategy
Luis Felipe Ensina, leading innovation in allergy and immunology
JOURNALS
Start Learning
Global Impact, Brazilian Roots: Prof. Ensina’s Journey Leading Innovation in Allergy and Immunology
New data from IMPACT-PLuS suggests early peanut oral immunotherapy has a lasting immunologic impact in children
JOURNALS
Start Learning
New data from IMPACT-PLuS suggests early peanut oral immunotherapy has a lasting immunologic impact in children
Mirikizumab, Crohn’s disease
JOURNALS
Start Learning
Mirikizumab maintains efficacy in patients with Crohn’s disease previously treated with ustekinumab: One-year results from VIVID-2
RMDs: Experts tell you what to expect in 2025
JOURNALS
Start Learning
RMDs: What to Expect in 2025
JOURNALS
Start Learning
EULAR launches 2024-2029 European manifesto to tackle rheumatic diseases

to view Favourites, Keep Notes and Track CME Credits

Favourites
Global Impact, Brazilian Roots: Prof. Ensina’s Journey Leading Innovation in Allergy and Immunology
View
Breakthrough treatments for hereditary angioedema revealed at EAACI 2024
View
B-cell depleting agent reduces risk of flares and increases chance of remission in IgG4-RD
View
UCB, making a difference in immunology
View
New data from IMPACT-PLuS suggests early peanut oral immunotherapy has a lasting immunologic impact in children
View
Treating moderate-to-severe atopic dermatitis in children and adolescents: Insights from the experts
View
Increased infliximab clearance in patients hospitalized with severe ulcerative colitis may lead to underexposure
View
Bimekizumab on structural damage in r-axial SpA & remote monitoring vs face-to-face
View
Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management
View
Efficacy and safety of izokibep: An investigational IL-17A inhibitor
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup